Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Smartphones in mental health: a critical review of background issues, current status and future concerns

    Research output: Contribution to journalReviewResearchpeer-review

  2. Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Smartphone-based self-monitoring in bipolar disorder: evaluation of usability and feasibility of two systems

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Pernille Kempel Ellegaard
  • Rasmus Wentzer Licht
  • Henrik Enghusen Poulsen
  • René Ernst Nielsen
  • Michael Berk
  • Olivia May Dean
  • Mohammadreza Mohebbi
  • Connie Thuroee Nielsen
View graph of relations

BACKGROUND: Oxidative stress and inflammation may be involved in the development and progression of mood disorders, including bipolar disorder. Currently, there is a scarcity of useful treatment options for bipolar depressive episodes, especially compared with the efficacy of treatment for acute mania. N-Acetylcysteine (NAC) has been explored for psychiatric disorders for some time given its antioxidant and anti-inflammatory properties. The current trial aims at testing the clinical effects of adjunctive NAC treatment (compared to placebo) for bipolar depression. We will also explore the biological effects of NAC in this context. We hypothesize that adjunctive NAC treatment will reduce symptoms of depression, which will be reflected by changes in selected markers of oxidative stress.

METHODS AND ANALYSIS: In the study, we will include adults diagnosed with bipolar disorder, in a currently depressive episode. Participants will undertake a 20-week, adjunctive, randomized, double-blinded, parallel group placebo-controlled trial comparing 3 grams of adjunctive NAC daily with placebo. The primary outcome is the mean change over time from baseline to end of study on the Montgomery-Asberg Depression Rating Scale (MADRS). Among the secondary outcomes are mean changes from baseline to end of study on the Bech-Rafaelsen Melancholia Scale (MES), the Young Mania Rating Scale (YMRS), the WHO-Five Well-being Index (WHO-5), the Global Assessment of Functioning scale (GAF-F), the Global Assessment of Symptoms scale (GAF-S) and the Clinical Global Impression-Severity scale (CGI-S). The potential effects on oxidative stress by NAC treatment will be measured through urine and blood samples. DNA will be examined for potential polymorphisms related to oxidative defences.

TRIAL REGISTRATION: Registered at The European Clinical Trials Database, NCT02294591 and The Danish Data Protection Agency: 2008-58-0035.

Original languageEnglish
JournalInternational Journal of Bipolar Disorders
Issue number1
Pages (from-to)11
Publication statusPublished - 5 Apr 2018

    Research areas

  • Journal Article

ID: 53711129